Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic Leukemia-Reference-Cited by-同舟云学术

Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic Leukemia

Published:2020-09-06 Issue:2 Volume:109 Page:424-432
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Gopalakrishnan Sathej¹,Wierda William²,Chyla Brenda³,Menon Rajeev¹,Miles Dale⁴,Humerickhouse Rod⁵,Awni Walid¹,Salem Ahmed Hamed¹⁶,Mensing Sven¹,Freise Kevin J.¹

Affiliation:

1. Clinical Pharmacology and Pharmacometrics AbbVie Inc. North Chicago Illinois USA

2. University of Texas MD Anderson Cancer Center Houston Texas USA

3. Oncology Biomarkers AbbVie Inc. North Chicago Illinois USA

4. Genentech Inc. South San Francisco California USA

5. Oncology Development AbbVie Inc. North Chicago Illinois USA

6. Clinical Pharmacy Faculty of Pharmacy Ain Shams University Cairo Egypt

Funder

Roche

AbbVie

Genentech

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2005

Reference42 articles.

1. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

2. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

3. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

4. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM

5. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting progression‐free survival from measurable residual disease in chronic lymphocytic leukemia;Clinical and Translational Science;2024-08

2. Quantitative systems pharmacology modeling of tumor heterogeneity in response to BH3‐mimetics using virtual tumors calibrated with cell viability assays;CPT: Pharmacometrics & Systems Pharmacology;2024-05-15

3. Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B‐cell lymphoma‐2 inhibitor;Clinical and Translational Science;2024-05

4. Pooled Population Pharmacokinetic Analyses of Venetoclax in Patients Across Indications and Healthy Subjects from Phase 1, 2, and 3 Clinical Trials;The Journal of Clinical Pharmacology;2023-05-23

5. Alternative strategies for optimizing treatment of chronic lymphocytic leukemia with complex clonal architecture;Leukemia Research;2021-11